Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors:: a randomized clinical trial

被引:23
作者
Bodri, D.
Vernaeve, V.
Guillen, J. J.
Vidal, R.
Figueras, F.
Coll, O.
机构
[1] Univ Barcelona, IDIBAPS, Clin EUGIN, Barcelona, Spain
[2] Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain
关键词
GnRH agonist; GnRH antagonist; IVF; oocyte donation; ovarian stimulation;
D O I
10.1093/humrep/del152
中图分类号
R71 [妇产科学];
学科分类号
100211 [妇产科学];
摘要
BACKGROUND: Little information is available on the outcome of controlled ovarian hyperstimulation (COH) using GnRH antagonist in oocyte donation cycles especially in comparison with the short GnRH agonist protocol. This study was aimed at comparing the two stimulation protocols in oocyte donation (OD) cycles. METHODS: A total of 113 donors randomly received COH using either GnRH antagonist or GnRH agonist. The primary endpoint was the mean number of mature oocytes retrieved per started donor cycle. Secondary endpoints were the mean number of cumulus-oocyte-complexes (COCs) retrieved, the mean proportion of mature oocytes, pregnancy and implantation rates in recipients. RESULTS: Oocytes were distributed to 166 recipients. The mean number (+/- SD) of COC (11.6 +/- 5.8 versus 12.1 +/- 6.7), mature oocytes (8.4 +/- 4.4 versus 8.9 +/- 5.3) and the proportion of mature oocytes (70.8 versus 75.7%) retrieved per started donor cycle were similar in the antagonist and agonist groups, respectively. The implantation rate (26.1 versus 30.1%), clinical (40.2 versus 45.6%) and ongoing pregnancy rate per recipient cycle (32.2 versus 37.9%) were comparable in antagonist and agonist protocols, respectively. CONCLUSIONS: Similar mean number of mature oocytes and comparable pregnancy rates are achieved after OD in which donors received COH using GnRH antagonist or short GnRH agonist protocols.
引用
收藏
页码:2246 / 2251
页数:6
相关论文
共 25 条
[1]
GnRH antagonist in assisted reproduction: a Cochrane review [J].
Al-Inany, H ;
Aboulghar, M .
HUMAN REPRODUCTION, 2002, 17 (04) :874-885
[2]
Ovarian stimulation with HMG:: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin [J].
Albano, C ;
Felberbaum, RE ;
Smitz, J ;
Riethmüller-Winzen, H ;
Engel, J ;
Diedrich, K ;
Devroey, P .
HUMAN REPRODUCTION, 2000, 15 (03) :526-531
[3]
[Anonymous], 1999, WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction
[4]
DELALLATA ES, 2004, GINECOL OBSTET MEX, V72, P53
[5]
Extrapituitary effects of GnRH antagonists in assisted reproduction: a review [J].
Engel, J ;
Riethmoller-Winzen, H ;
Diedrich, K .
REPRODUCTIVE BIOMEDICINE ONLINE, 2005, 10 (02) :230-234
[6]
*EUR ORG STUD GROU, 2001, HUM REPROD, V15, P1490
[7]
Felberbaum Ricardo E, 2003, Reprod Biomed Online, V6, P43
[8]
Intracytoplasmic sperm injection: laboratory set-up and injection procedure [J].
Joris, H ;
Nagy, Z ;
Van de Velde, H ;
De Vos, A ;
Van Steirteghem, A .
HUMAN REPRODUCTION, 1998, 13 :76-86
[9]
High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles [J].
Kol, S ;
Lightman, A ;
Hillensjo, T ;
Devroey, P ;
Fauser, B ;
Tarlatzis, B ;
Mannaerts, B ;
Itskovitz-Eldor, J .
HUMAN REPRODUCTION, 1999, 14 (09) :2242-2244
[10]
Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists [J].
Kolibianakis, EM ;
Bourgain, C ;
Plattea, P ;
Albano, C ;
Van Steirteghem, AC ;
Devroey, P .
FERTILITY AND STERILITY, 2003, 80 (02) :464-466